Compass Therapeutics, Inc. (CMPX)
(Real Time Quote from BATS)
$1.16 USD
0.00 (0.00%)
Updated Aug 16, 2024 12:54 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Compass Therapeutics, Inc. (CMPX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.00 | $10.00 | $5.00 | 589.66% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Compass Therapeutics, Inc. comes to $8.00. The forecasts range from a low of $5.00 to a high of $10.00. The average price target represents an increase of 589.66% from the last closing price of $1.16.
Analyst Price Targets (6 )
Broker Rating
Compass Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 71.43% and 14.29% of all recommendations. A month ago, Strong Buy made up 71.43%, while Buy represented 14.29%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CMPX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.43 | 1.43 | 1.43 | 1.43 | 1.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
8/6/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
7/24/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
5/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 7 |
Average Target Price | $8.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 74 of 253 |
Current Quarter EPS Est: | -0.11 |